A single peer-reviewed study tested a faster genomic workflow in children with suspected or confirmed cancer. Average time from sample collection to a clinical report was 3 days with rapid testing, against 42 days with the standard workflow. Clinicians recorded management changes in part of the prospective group. The result concerns faster diagnostic information; the small, non-randomised study did not establish longer survival.
A faster workflow brought genomic reports into the time available for early childhood cancer decisions. In a single peer-reviewed study, the mean interval from obtaining a sample to issuing its report shrank to 3 days from 42 days. Whole-genome sequencing examines genetic information across the genome. The researchers assessed 54 children with suspected or confirmed malignancy, using both newly collected and archived specimens.[1]
Rapid sequencing in 104 samples representing 37 disease entities detected 147 of the 155 clinical variants identified in the comparison. Standard clinical testing detected 138. Some findings missed by the rapid method involved low variant proportions or differences within a tumour. Other detected changes preserved the diagnoses in those cases. For central nervous system tumours, methylation testing remained a separate measurement rather than being absorbed into genome sequencing.[1]
Clinicians recorded an effect on management for 17 of the 35 prospectively assessed children, including earlier targeted-treatment consideration and avoiding unnecessary escalation. Those assessments track decisions. The small single-centre comparison used no random assignment and did not establish a survival gain. Longer-term outcomes and the expense of wider implementation need separate evaluation.[1]
